5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
Abstract Introduction: Patients with schizophrenia characteristically exhibit cognitive deficits. The level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. The purpose of this study was to assess...
Main Authors: | Neyousha Mohammadi, Maryam Noroozian, Naregs Karamghadiri, Shahin Akhondzadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Iran University of Medical Sciences
2010-01-01
|
Series: | Basic and Clinical Neuroscience |
Subjects: | |
Online Access: | http://bcn.tums.ac.ir/browse.php?a_code=A-10-1-19&slc_lang=en&sid=1 |
Similar Items
-
5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
by: Neyousha Mohammadi, et al.
Published: (2010-01-01) -
The therapeutic effect of quetiapine on cognitive impairment associated with 5-HT1A presynaptic receptor involved schizophrenia
by: Dai Han, Shenxun Shi, Hong Luo
Published: (2019-09-01) -
Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial
by: Mohammadi Mohammad, et al.
Published: (2003-06-01) -
A triple-blinded, randomized, placebo-controlled trial to examine the efficacy of buspirone added to typical antipsychotic drugs in patients with chronic schizophrenia
by: Fatemeh Sheikhmoonesi, et al.
Published: (2015-01-01) -
Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Somaye Arabzadeh, et al.
Published: (2018-02-01)